Items where Funder is PROSTATE CANCER UK.

6961

Scott, E., Hodgson, K., Calle, B. orcid.org/0000-0002-9893-9803 et al. (56 more authors) (2023) Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene, 42. pp. 926-937. ISSN 0950-9232

RIA16-ST2-022

Al-janabi, H., Moyes, K., Allen, R. et al. (14 more authors) (2024) Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12 (7). e009368. ISSN 2051-1426

Coulton, A., Murai, J., Qian, D. et al. (3 more authors) (2024) Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response. Nature Communications, 15. 5665. ISSN 2041-1723

RIA21-ST2-006

Bastian, K., Orozco‐Moreno, M., Thomas, H. et al. (26 more authors) (2025) FUT8 is a critical driver of prostate tumour growth and can be targeted using fucosylation inhibitors. Cancer Medicine, 14 (10). e70959. ISSN 2045-7634

Scott, E., Hodgson, K., Calle, B. orcid.org/0000-0002-9893-9803 et al. (56 more authors) (2023) Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene, 42. pp. 926-937. ISSN 0950-9232